DDI-DrugBank.d739.s0 >> Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate). >> 0-10,176-187
DDI-DrugBank.d739.s1 >> - did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio). >> 48-55,158-165
DDI-DrugBank.d739.s2 >> - did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin. >> 84-90
DDI-DrugBank.d739.s3 >> - did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. >> 53-63,105-116,218-228
DDI-DrugBank.d739.s4 >> Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. >> 0-10,167-179,192-204,219-227
DDI-DrugBank.d739.s5 >> - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone. >> 72-81,86-97,139-148,165-176
DDI-DrugBank.d739.s6 >> Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. >> 0-12,70-80,133-143
DDI-DrugBank.d739.s7 >> No dosage adjustment for montelukast is recommended. >> 25-35
DDI-DrugBank.d739.s8 >> It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. >> 112-124,129-136,164-174
DDI-DrugBank.d739.s9 >> Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no apparent increase in adverse reactions. >> 0-10
DDI-DrugBank.d739.s10 >> In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. >> 62-72,164-175,178-187,190-201,209-222,225-237,244-260,271-281,284-290,297-304
DDI-DrugBank.d739.s11 >> Although additional specific interaction studies were not performed, montelukast was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions. >> 69-79
DDI-DrugBank.d739.s12 >> These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. >> 27-42,45-62,65-102,105-119,126-138
DDI-DrugBank.d739.s13 >> Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. >> 0-12,70-80,133-143
DDI-DrugBank.d739.s14 >> No dosage adjustment for montelukast is recommended. >> 25-35
DDI-DrugBank.d739.s15 >> It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. >> 112-124,129-136,164-174
